journal
https://read.qxmd.com/read/38430549/novel-molecular-subtypes-of-intracranial-germ-cell-tumours-expand-therapeutic-opportunities
#21
JOURNAL ARTICLE
Bo Li, Shuang Zhao, Shouwei Li, Chunde Li, Wei Liu, Lin Li, Bowen Cui, Xing Liu, Huiyuan Chen, Jing Zhang, Yin Ren, Fei Liu, Ming Yang, Tao Jiang, Yu Liu, Xiaoguang Qiu
BACKGROUND: Intracranial germ cell tumours (IGCTs) are a rare group of malignancies that are clinically classified as germinomas and nongerminomatous germ cell tumours (NGGCTs). Previous studies have found that somatic mutations involving the MAPK/mTOR signalling pathway are common early events. However, a comprehensive genomic understanding of IGCTs is still lacking. METHODS: We established a cohort including over 100 IGCTs and conducted genomic and transcriptomic sequencing...
March 2, 2024: Neuro-oncology
https://read.qxmd.com/read/38417064/lymphatic-endothelial-like-cells-in-the-glioblastoma-tumor-niche-drive-metabolic-alterations-that-promote-stem-cell-proliferation-and-survival
#22
JOURNAL ARTICLE
Reilly L Kidwell, Manish K Aghi
No abstract text is available yet for this article.
February 28, 2024: Neuro-oncology
https://read.qxmd.com/read/38416702/secreted-clusterin-inhibits-tumorigenesis-by-modulating-tumor-cell-and-macrophage-in-human-meningioma
#23
JOURNAL ARTICLE
Chao Ke, Boya Huang, Jian Xiang, Jinlian Liang, Guangjie Wu, Minghui Qiu, Kai Cheng, Lipeng Mao, Wen Lei, Yang Hu, Xiaogen Tang, Yizhen Tian, Guobing Chen, Oscar Junhong Luo, Hongyi Zhang
BACKGROUND: Meningioma is the most common primary intracranial tumor with high frequency of postoperative recurrence, yet the biology of meningioma malignancy process is still obscure. METHODS: To identify potential therapeutic targets and tumor suppressors, we performed single-cell transcriptome analysis through meningioma malignancy, which included 18 samples spanning normal meninges, benign and high grade in situ tumors, and lung metastases, for extensive transcriptome characterization...
February 28, 2024: Neuro-oncology
https://read.qxmd.com/read/38411438/sexual-biased-necroinflammation-is-revealed-as-a-predictor-of-bevacizumab-benefit-in-glioblastoma
#24
JOURNAL ARTICLE
Sara Hiller-Vallina, Lucia Mondejar-Ruescas, Marta Caamaño-Moreno, Blanca Cómitre-Mariano, Denisse Alcivar-López, Juan M Sepulveda, Aurelio Hernández-Laín, Ángel Pérez-Núñez, Berta Segura-Collar, Ricardo Gargini
BACKGROUND: Glioblastoma (GBM) is a highly malignant brain tumor that affects men more often than women. In addition, the former shows a poorer survival prognosis. To date the reason for this sex-specific aggressiveness remains unclear. Therefore, the aim of this study is to investigate tumor processes that explain these sex differences. METHODS: This was a retrospective study of GBM patients which was stratified according to sex. Cohort with 73 tumors were analyzed with immunohistochemistry, RNA-seq and RT-qPCR to characterize differences in vascular and immunological profiles...
February 27, 2024: Neuro-oncology
https://read.qxmd.com/read/38400780/safety-and-pharmacokinetics-of-onc201-dordaviprone-administered-two-consecutive-days-per-week-in-pediatric-patients-with-h3k27m-mutant-glioma
#25
JOURNAL ARTICLE
Yazmin Odia, Carl Koschmann, Nicholas A Vitanza, Peter de Blank, Dolly Aguilera, Jeffrey Allen, Doured Daghistani, Matthew Hall, Ziad Khatib, Cassie Kline, Tobey MacDonald, Sabine Mueller, Shamia L Faison, Joshua E Allen, Odin J Naderer, Samuel C Ramage, Rohinton S Tarapore, Susan Lynne McGovern, Soumen Khatua, Wafik Zaky, Sharon L Gardner
BACKGROUND: This study evaluated the safety and pharmacokinetics (PK) of oral ONC201 administered twice-weekly on consecutive days (D1D2) in pediatric patients with newly diagnosed DIPG and/or recurrent/refractory H3 K27M glioma. METHODS: This phase 1 dose-escalation and expansion study included pediatric patients with H3 K27M-mutant glioma and/or DIPG following ≥1 line of therapy (NCT03416530). ONC201 was administered D1D2 at three dose levels (DLs; -1, 1, and 2)...
February 24, 2024: Neuro-oncology
https://read.qxmd.com/read/38395429/corrigendum-to-consensus-framework-for-conducting-phase-i-ii-clinical-trials-for-children-adolescents-and-young-adults-with-pediatric-low-grade-glioma-guidelines-established-by-the-international-pediatric-low-grade-glioma-coalition-clinical-trial-working-group
#26
https://read.qxmd.com/read/38394444/cancer-stem-cell-hypothesis-2-0-in-glioblastoma-where-are-we-now-and-where-are-we-going
#27
JOURNAL ARTICLE
Anthony R Sloan, Daniel J Silver, Sam Kint, Marco Gallo, Justin D Lathia
Over the past 2 decades, the cancer stem cell (CSC) hypothesis has provided insight into many malignant tumors, including glioblastoma (GBM). Cancer stem cells have been identified in patient-derived tumors and in some mouse models, allowing for a deeper understanding of cellular and molecular mechanisms underlying GBM growth and therapeutic resistance. The CSC hypothesis has been the cornerstone of cellular heterogeneity, providing a conceptual and technical framework to explain this longstanding phenotype in GBM...
February 23, 2024: Neuro-oncology
https://read.qxmd.com/read/38386699/selective-drd2-antagonist-and-clpp-agonist-onc201-in-a-recurrent-non-midline-h3-k27m-mutant-glioma-cohort
#28
JOURNAL ARTICLE
Yazmin Odia, Matthew D Hall, Timothy Francis Cloughesy, Patrick Y Wen, Isabel Arrillaga-Romany, Doured Daghistani, Minesh P Mehta, Rohinton S Tarapore, Samuel C Ramage, Joshua E Allen
BACKGROUND: Diffuse midline glioma, H3 K27-altered (H3 K27M-altered DMG) are invariably lethal, disproportionately affecting the young and without effective treatment besides radiotherapy. The 2016 WHO CNS Tumors Classification defined H3K27M mutations as pathognomonic but restricted diagnosis to diffuse gliomas involving midline structures by 2018. Dordaviprone (ONC201) is an oral investigational small molecule, DRD2 antagonist and ClpP agonist associated with durable responses in recurrent H3K27M-mutant DMG...
February 22, 2024: Neuro-oncology
https://read.qxmd.com/read/38366877/corrigendum-to-consensus-framework-for-conducting-phase-i-ii-clinical-trials-for-children-adolescents-and-young-adults-with-pediatric-low-grade-glioma-guidelines-established-by-the-international-pediatric-low-grade-glioma-coalition-clinical-trial-working-group
#29
https://read.qxmd.com/read/38366847/dual-p38mapk-and-mek-inhibition-disrupts-adaptive-chemoresistance-in-mesenchymal-glioblastoma-to-temozolomide
#30
JOURNAL ARTICLE
Hong Sheng Cheng, Yuk Kien Chong, Eldeen Kai Yi Lim, Xin Yi Lee, Qing You Pang, Wisna Novera, Charlie Marvalim, Jeannie Xue Ting Lee, Beng Ti Ang, Carol Tang, Nguan Soon Tan
BACKGROUND: Precision treatment of glioblastoma is increasingly focused on molecular subtyping, with the mesenchymal subtype particularly resistant to temozolomide. Here, we aim to develop a targeted therapy for temozolomide resensitization in the mesenchymal subtype. METHODS: We integrated kinomic profiles and kinase inhibitor screens from patient-derived proneural and mesenchymal glioma-propagating cells public clinical datasets to identify key protein kinases implicated in temozolomide resistance...
February 16, 2024: Neuro-oncology
https://read.qxmd.com/read/38366824/interim-fdg-pet-improves-treatment-failure-prediction-in-primary-central-nervous-system-lymphoma-a-loc-network-prospective-multicentric-study
#31
JOURNAL ARTICLE
Laura Rozenblum, Caroline Houillier, Amandine Baptiste, Carole Soussain, Véronique Edeline, Philippe Naggara, Marine Soret, Valérie Causse-Lemercier, Lise Willems, Sylvain Choquet, Renata Ursu, Damien Galanaud, Lisa Belin, Khê Hoang-Xuan, Aurélie Kas
PURPOSE: The purpose of our study was to assess the predictive and prognostic role of 2-18F-fluoro-2-deoxy-D-glucose (FDG) PET/MRI during high-dose methotrexate-based chemotherapy (HD-MBC) in de novo primary central nervous system lymphoma (PCNSL) patients aged 60 and above. METHODS: This prospective multicentric ancillary study included 65 immunocompetents patients who received induction HD-MBC as part of the BLOCAGE01 phase III trial. FDG-PET/MRI were acquired at baseline, post two cycles (PET/MRI2), and post-treatment (PET/MRI3)...
February 16, 2024: Neuro-oncology
https://read.qxmd.com/read/38363979/distinct-uptake-and-elimination-profiles-for-trastuzumab-human-igg-and-biocytin-tmr-in-experimental-her2-brain-metastases-of-breast-cancer
#32
JOURNAL ARTICLE
Vanesa L Silvestri, Andy D Tran, Monika Chung, Natalie Chung, Brunilde Gril, Christina Robinson, Simone Difilippantonio, Debbie Wei, Michael J Kruhlak, Cody J Peer, W Douglas Figg, Imran Khan, Patricia S Steeg
BACKGROUND: The aim of this study is an improved understanding of drug distribution in brain metastases. Rather than single point snapshots, we analyzed the time course and route of drug/probe elimination (clearance), focusing on the Intramural Periarterial Drainage (IPAD) pathway. METHODS: Mice with JIMT1-BR HER2+ experimental brain metastases were injected with biocytin-TMR and either trastuzumab or human IgG. Drugs/probes circulated for 5 min-48h, followed by perfusion...
February 13, 2024: Neuro-oncology
https://read.qxmd.com/read/38345188/correction-to-whole-tumor-analysis-reveals-early-origin-of-the-tert-promoter-mutation-and-intercellular-heterogeneity-in-tert-expression
#33
(no author information available yet)
No abstract text is available yet for this article.
February 12, 2024: Neuro-oncology
https://read.qxmd.com/read/38339859/endoplasmic-reticulum-stress-related-cancer-associated-fibroblast-confers-adverse-prognosis-and-therapeutic-vulnerability-in-skull-base-chordoma
#34
JOURNAL ARTICLE
Mingxuan Li, Yujia Xiong, Jiwei Bai, Yazhuo Zhang
No abstract text is available yet for this article.
February 10, 2024: Neuro-oncology
https://read.qxmd.com/read/38339843/the-greatest-challenge-for-pediatric-low-grade-glioma
#35
JOURNAL ARTICLE
Daniel C Moreira, Eric Bouffet, Ibrahim Qaddoumi
No abstract text is available yet for this article.
February 10, 2024: Neuro-oncology
https://read.qxmd.com/read/38334125/unraveling-the-complexity-of-the-senescence-associated-secretory-phenotype-in-adamantinomatous-craniopharyngioma-using-multi-modal-machine-learning-analysis
#36
JOURNAL ARTICLE
Eric W Prince, John R Apps, John Jeang, Keanu Chee, Stephen Medlin, Eric M Jackson, Roy Dudley, David Limbrick, Robert Naftel, James Johnston, Neil Feldstein, Laura M Prolo, Kevin Ginn, Toba Niazi, Amy Smith, Lindsay Kilburn, Joshua Chern, Jeffrey Leonard, Sandi Lam, David S Hersh, Jose Mario Gonzalez-Meljem, Vladimir Amani, Andrew M Donson, Siddhartha S Mitra, Pratiti Bandohpadhayay, Juan Pedro Martinez-Barbera, Todd C Hankinson
BACKGROUND: Cellular senescence can have positive and negative effects on the body, including aiding in damage repair and facilitating tumor growth. Adamantinomatous Craniopharyngioma (ACP), the most common pediatric sellar/suprasellar brain tumor, poses significant treatment challenges. Recent studies suggest that senescent cells in ACP tumors may contribute to tumor growth and invasion by releasing a Senesecence-Associated Secretory Phenotype (SASP). However, a detailed analysis of these characteristics has yet to be completed...
February 9, 2024: Neuro-oncology
https://read.qxmd.com/read/38333920/expression-of-concern-microrna-7-upregulates-death-receptor-5-and-primes-resistant-brain-tumors-to-caspase-mediated-apoptosis
#37
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
February 9, 2024: Neuro-oncology
https://read.qxmd.com/read/38290484/targeted-therapy-done-right-direct-shh-inhibition-for-shh-medulloblastoma
#38
EDITORIAL
Anandani Nellan, Sadhana Jackson
No abstract text is available yet for this article.
January 30, 2024: Neuro-oncology
https://read.qxmd.com/read/38290471/trem2-function-in-glioblastoma-immune-microenvironment-can-we-distinguish-reality-from-illusion
#39
EDITORIAL
Sourav Ghosh, Carla V Rothlin
No abstract text is available yet for this article.
January 30, 2024: Neuro-oncology
https://read.qxmd.com/read/38285679/glioblastoma-and-radiotherapy-a-multi-center-ai-study-for-survival-predictions-from-mri-grasp-study
#40
JOURNAL ARTICLE
Alysha Chelliah, David A Wood, Liane S Canas, Haris Shuaib, Stuart Currie, Kavi Fatania, Russell Frood, Chris Rowland-Hill, Stefanie Thust, Stephen J Wastling, Sean Tenant, Karen Foweraker, Matthew Williams, Qiquan Wang, Andrei Roman, Carmen Dragos, Mark MacDonald, Yue Hui Lau, Christian A Linares, Ahmed Bassiouny, Aysha Luis, Thomas Young, Juliet Brock, Edward Chandy, Erica Beaumont, Tai-Chung Lam, Liam Welsh, Joanne Lewis, Ryan Mathew, Eric Kerfoot, Richard Brown, Daniel Beasley, Jennifer Glendenning, Lucy Brazil, Angela Swampillai, Keyoumars Ashkan, Sébastien Ourselin, Marc Modat, Thomas C Booth
BACKGROUND: The aim was to predict survival of glioblastoma at eight months after radiotherapy (a period allowing for completing a typical course of adjuvant temozolomide), by applying deep learning to the first brain MRI after radiotherapy completion. METHODS: Retrospective and prospective data were collected from 206 consecutive glioblastoma, IDH-wildtype patients diagnosed between March 2014-February 2022 across 11 UK centers. Models were trained on 158 retrospective patients from three centers...
January 29, 2024: Neuro-oncology
journal
journal
34661
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.